Benevento BT, Sipski ML Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with spinal cord injury. Phys Ther. 2002 Jun;82(6):601-12. Review.
D'Hondt F, Everaert K Urinary tract infections in patients with spinal cord injuries. Curr Infect Dis Rep. 2011 Dec;13(6):544-51. doi: 10.1007/s11908-011-0208-6.
Ersoz M, Tunc H, Akyuz M, Ozel S Bladder storage and emptying disorder frequencies in hemorrhagic and ischemic stroke patients with bladder dysfunction. Cerebrovasc Dis. 2005;20(5):395-9. Epub 2005 Oct 3.
Gupta A, Taly AB, Srivastava A, Murali T Non-traumatic spinal cord lesions: epidemiology, complications, neurological and functional outcome of rehabilitation. Spinal Cord. 2009 Apr;47(4):307-11. doi: 10.1038/sc.2008.123. Epub 2008 Oct 21.
Jamison J, Maguire S, McCann J Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev. 2013 Nov 18;(11):CD004375. doi: 10.1002/14651858.CD004375.pub4. Review.
Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother. 2006 Jun;50(6):2251-4.
Magasi P, Pánovics J, Illés A, Nagy M Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol. 1994;26(2):137-40.
Morawietz C, Moffat F Effects of locomotor training after incomplete spinal cord injury: a systematic review. Arch Phys Med Rehabil. 2013 Nov;94(11):2297-308. doi: 10.1016/j.apmr.2013.06.023. Epub 2013 Jul 9. Review.
Naber KG, Cho YH, Matsumoto T, Schaeffer AJ Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009 Feb;33(2):111-9. doi: 10.1016/j.ijantimicag.2008.08.011. Epub 2008 Oct 28. Review.
Plowman, R , Graves, N., Griffin, M., Swan, A., Cookson, B., Taylor, L. 1999. The socio-economic burden of healthcare associated infection. PHLS.
Richie, J and Spencer, L. Qualitative data analysis for applied policy research. In Analysing Qualitative Data. (eds A.Bryman and R.Burgess). 1994:173-194. London: Routledge
Rubin SM Management of multiple sclerosis: an overview. Dis Mon. 2013 Jul;59(7):253-60. doi: 10.1016/j.disamonth.2013.03.012. Review.
Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009 Nov;34(5):407-13. doi: 10.1016/j.ijantimicag.2009.04.012. Epub 2009 Jun 7.
Sedor J, Mulholland SG Hospital-acquired urinary tract infections associated with the indwelling catheter. Urol Clin North Am. 1999 Nov;26(4):821-8. Review.
Street JT, Noonan VK, Cheung A, Fisher CG, Dvorak MF Incidence of acute care adverse events and long-term health-related quality of life in patients with TSCI. Spine J. 2015 May 1;15(5):923-32. doi: 10.1016/j.spinee.2013.06.051. Epub 2013 Aug 24.
Tammen H Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group. Br J Urol. 1990 Jan;65(1):6-9.
Werndle MC, Zoumprouli A, Sedgwick P, Papadopoulos MC Variability in the treatment of acute spinal cord injury in the United Kingdom: results of a national survey. J Neurotrauma. 2012 Mar 20;29(5):880-8. doi: 10.1089/neu.2011.2038. Epub 2011 Oct 26.
West TW Transverse myelitis--a review of the presentation, diagnosis, and initial management. Discov Med. 2013 Oct;16(88):167-77. Review.
Willing BP, Russell SL, Finlay BB Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol. 2011 Apr;9(4):233-43. doi: 10.1038/nrmicro2536. Epub 2011 Feb 28. Review.
Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
